Research notes

The report issues a technical BUY call on VBL with stoploss 433 and targets of 455 and 463.

The report issues a technical SELL call on Aurobindo Pharma with stoploss 1715 and targets of 1600 and 1575.

The report expects revenue to grow 29.9% YoY though EBITDA margin is seen declining 710.7bps YoY to 23.4%.

The report expects APAT to rise 228.8% YoY despite EBITDA margin contraction of 187.3bps QoQ.

The report expects revenue to grow 37.7% YoY but EBITDA margin to contract 406.3bps QoQ to 20.5%.

The report expects EBITDA margin to fall 349.5bps QoQ to 7.5% despite 20% YoY revenue growth.

The report expects APAT to rise sharply YoY and the rating was revised down from BUY to REDUCE with a raised target price.

The report expects revenue to rise 38.5% YoY driven by ramp-up in the CDMO business.

The report expects per-unit EBITDA to fall to INR 24.5/kg from INR 35.0/kg in Q1 despite 32.8% YoY revenue growth.

The report expects EBITDA margin to decline 276.8bps QoQ to 22.6% despite 22% YoY revenue growth.

The report expects revenue to grow 31% YoY but EBITDA margin to fall 417bps QoQ to 16.8%; the rating was revised from SELL to REDUCE.

The report expects EBITDA margin to contract 335.4bps QoQ due to higher raw material prices and high-cost inventory.

The report expects EBITDA margin to decline 452.7bps QoQ to 20.9% despite 30% YoY revenue growth.

The report expects revenue and EBITDA to grow YoY and QoQ with EBITDA margin broadly stable at 34.2%.

The report expects EBITDA margin to fall 406.9bps QoQ due to correction in finished product prices and higher energy costs despite falling ammonia prices.

The report expects revenue and EBITDA to grow over 22% YoY, aided by improved Baker Hughes contract revenue.

The report expects revenue to rise 14.4% YoY but EBITDA margin to contract 145.3bps QoQ due to higher raw material prices.

The report states that PEPL's H1FY27 presales of INR 72.3bn grew 20% YoY, collections rose 16% YoY, retail occupancy stood at 99%, and a launch pipeline of over INR 400bn for H2FY27 supports achieving FY27 presales guidance of INR 350bn, while maintaining a BUY rating with a target price of INR 1,878.

The report notes Sun Pharma approved a plan to raise up to Rs 10,000 crore via NCDs for funding and business expansion.

The report notes Shyam Metalics secured strategic mining rights for the Phutamura coal block via investment in Alom Solar Private Limited.

The report notes Vimag Labs commenced production at its Haryana facility and plans to invest Rs 50 crore to expand operations.

The report notes KPIL secured new T&D orders worth Rs 2,225 crore, strengthening its order book.

The report notes Vantrock plans to invest Rs 3,000 crore over four years to develop logistics and warehousing parks.

The report lists Max Healthcare Institute among the top losers on 13 Oct, down 0.57-0.99%.

The report lists Maruti Suzuki India among the top losers on 13 Oct, down 0.57-0.99%.